PR Newswire Clinical TrialsOriginal article
Mercy BioAnalytics Receives FDA Approval to Initiate Prospective Pivotal Study of Evident™Ovarian Cancer Screening Test
RegulatoryapprovedEvident™Positive
AI Analysis
Summary
Mercy BioAnalytics received FDA IDE approval to initiate the SOARA pivotal clinical validation study for its Evident ovarian cancer screening test for average-risk women. The approval enables the company to proceed with the prospective study following Institutional Review Board clearance.
Clinical Trial Data
Phase
pivotal
Outcome Details
FDA IDE approval received to initiate prospective pivotal study
Importance:7/10
Sentiment:
0.80
FDA approvalIDE approvalovarian cancerscreening testclinical validationpivotal study
Read the original article
Published by PR Newswire Clinical Trials on September 21, 2026 5:27 PM